MedTrace Logo

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

NCT01852890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-24

No results posted yet for this study

Summary

This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for treatment of pancreatic cancer.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

Ascorbate

Intravenous infusion of high-dose ascorbate

DRUG

Gemcitabine

Intravenous chemotherapeutic

RADIATION

Radiation therapy

Sponsors & Collaborators

  • Holden Comprehensive Cancer Center

    collaborator OTHER

  • Gateway for Cancer Research

    collaborator OTHER

  • Joseph J. Cullen

    lead OTHER

Principal Investigators

  • Joseph J Cullen, MD, FACS · The University of Iowa Hospitals & Clinics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-01-22
Completion
2025-10-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01852890 on ClinicalTrials.gov